Authors
Latest:
Dr. Maziéres on the Evaluation of Tepotinib Plus Osimertinib in EGFR-mutated NSCLCJulien Maziéres, MD, PhD, discusses the evaluation of tepotinib plus osimertinib in EGFR-mutated non–small cell lung cancer.
Latest:
Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in MelanomaMattia Garutti, MD, discusses the potential shift to neoadjuvant therapy in melanoma.
Latest:
Review of the SELECT-AML-1 Trial and the Future of Newly Diagnosed AMLDaniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.
Latest:
Dr. Azad on the Significance of the PROfound Trial in mCRPCArun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.
Latest:
Dr. Farrington on the Importance of Genetic Testing in CRCCaroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.
Latest:
Basal Cell Carcinoma Clinical PearlsDrs Babakoohi and Atlas share clinical pearls for community oncologists on treating basal cell carcinoma.
Latest:
Dr. Wang on the Rationale for Viral Hepatitis Screening to Prevent HCCSu H. Wang, MD, MPH, discusses the rationale for the integration of viral hepatitis screening and care in a hospital system as the first steps for preventing liver cancers like hepatocellular carcinoma.
Latest:
Dr. Jones on the Importance of Immune Checkpoint Inhibitors in CRCJeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.
Latest:
Dr. Lister on Selecting Patients With Lymphoma for CAR T-Cell TherapyJohn Lister, MD, discusses selecting patients with lymphoma for CAR T-cell therapy.
Latest:
Dr. Nguyen on Treatment Considerations in High-Risk Prostate CancerPaul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.
Latest:
Dr. Fleury on the Advancement of Decentralized Clinical Trials During COVID-19Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.
Latest:
Dr. McKay on the Rationale for Triplet Frontline Therapy in RCCRana R. McKay, MD, discusses the pros and cons of utilizing triplet therapy in the frontline treatment of patients with renal cell carcinoma.
Latest:
Dr. Modi on Trastuzumab Deruxtecan in HER2-low Breast CancerShanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.
Latest:
Student Loan Debt, Immigration Status Often Drive Career Decisions for FellowsInvestigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.
Latest:
Testing for PSMA in Community SettingsScott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.
Latest:
Research on CAR T Therapy in Earlier Lines of TreatmentAmit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.
Latest:
Dr. Bezerra on Barriers to Enrollment for Clinical Trials in B-Cell NHLEvandro D. Bezerra, MD, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma who have progressed on anti-CD19 CAR T-cell therapy.
Latest:
Dr. DeCaprio on Raising Awareness in Merkel Cell CarcinomaJames A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.
Latest:
Dr. Ahn on Choosing Between Treatment Options in CLLInhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.
Latest:
First-Line Treatment Options for Lower-Risk MDSThomas Cluzeau, MD, PhD provides an overview of first-line treatment options for symptomatic anemia in patients with lower-risk MDS, followed by a discussion of panelists’ treatment patterns and dosing strategies across the globe.
Latest:
Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid TumorsAurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.
Latest:
Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CISKarim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.
Latest:
Dr. Vaishampayan on the Rationale of the PROBE Trial in RCCUlka Nitin Vaishampayan, MBBS, discusses the rationale of the phase 3 PROBE trial in advanced renal cell carcinoma.
Latest:
Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic CancerWen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.
Latest:
Steroid Refractory Acute GvHD and REACH TrialsAn overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.
Latest:
Future Treatment Landscape of AMLCorey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Latest:
Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLCDavid Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).
Latest:
Evolving Treatment Landscape of HER2+ Metastatic Breast CancerClosing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.
Latest:
Dr. Kimmick on Selecting Adjuvant Therapy for Patients With HER2+ Breast CancerGretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.
Latest:
ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment LandscapeFollowing the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.
